Treatment-related gastrointestinal toxicities and advanced colorectal or pancreatic cancer: A critical update

por Aprile, Giuseppe, Rihawi, Karim, De Carlo, Elisa, Sonis, Stephen T
Publicado no World J Gastroenterol (2015)

Ramucirumab: preclinical research and clinical development

por Aprile, Giuseppe, Rijavec, Erika, Fontanella, Caterina, Rihawi, Karim, Grossi, Francesco
Publicado no Onco Targets Ther (2014)

Chemotherapy treatment in malignant pleural mesothelioma: a difficult history

por Cinausero, Marika, Rihawi, Karim, Sperandi, Francesca, Melotti, Barbara, Ardizzoni, Andrea
Publicado no J Thorac Dis (2018)

Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence

por Rihawi, Karim, Gelsomino, Francesco, Sperandi, Francesca, Melotti, Barbara, Fiorentino, Michelangelo, Casolari, Laura, Ardizzoni, Andrea
Publicado no Ther Adv Respir Dis (2017)

Treatment of Metastatic Breast Cancer in a Real-World Scenario: Is Progression-Free Survival With First Line Predictive of Benefit From Second and Later Lines?

por Bonotto, Marta, Gerratana, Lorenzo, Iacono, Donatella, Minisini, Alessandro Marco, Rihawi, Karim, Fasola, Gianpiero, Puglisi, Fabio
Publicado no Oncologist (2015)

Hyperglycemia and Phosphatidylinositol 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) Inhibitors in Phase I Trials: Incidence, Predictive Factors, and Mana...

por Khan, Khurum H., Wong, Mabel, Rihawi, Karim, Bodla, Shankar, Morganstein, Daniel, Banerji, Udai, Molife, Lulama R.
Publicado no Oncologist (2016)

Novel HER2-Directed Treatments in Advanced Gastric Carcinoma: AnotHER Paradigm Shift?

por Ricci, Angela Dalia, Rizzo, Alessandro, Rojas Llimpe, Fabiola Lorena, Di Fabio, Francesca, De Biase, Dario, Rihawi, Karim
Publicado no Cancers (Basel) (2021)

Real-time tests of multiple genome alterations take the first steps into the clinic: a learning example

por Gerratana, Lorenzo, De Maglio, Giovanna, De Pellegrin, Alessandro, Follador, Alessandro, Rihawi, Karim, Pizzolitto, Stefano, Puglisi, Fabio, Fasola, Gianpiero
Publicado no Onco Targets Ther (2016)

Roles of IL-1 in Cancer: From Tumor Progression to Resistance to Targeted Therapies

por Gelfo, Valerio, Romaniello, Donatella, Mazzeschi, Martina, Sgarzi, Michela, Grilli, Giada, Morselli, Alessandra, Manzan, Beatrice, Rihawi, Karim, Lauriola, Mattia
Publicado no Int J Mol Sci (2020)

Reliability of programmed death ligand 1 (PD-L1) tumor proportion score (TPS) on cytological smears in advanced non-small cell lung cancer: a prospective validation study

por Ricci, Costantino, Capizzi, Elisa, Giunchi, Francesca, Casolari, Laura, Gelsomino, Francesco, Rihawi, Karim, Natali, Filippo, Livi, Vanina, Trisolini, Rocco, Fiorentino, Michelangelo, Ardizzoni, Andrea
Publicado no Ther Adv Med Oncol (2020)

Tumor-Associated Macrophages and Inflammatory Microenvironment in Gastric Cancer: Novel Translational Implications

por Rihawi, Karim, Ricci, Angela Dalia, Rizzo, Alessandro, Brocchi, Stefano, Marasco, Giovanni, Pastore, Luigi Vincenzo, Llimpe, Fabiola Lorena Rojas, Golfieri, Rita, Renzulli, Matteo
Publicado no Int J Mol Sci (2021)

Higher risk of infections with PI3K-AKT-mTOR pathway inhibitors in patients with advanced solid tumors on Phase I clinical trials

por Rafii, Saeed, Roda, Desamparados, Geuna, Elena, Jimenez, Begona, Rihawi, Karim, Capelan, Marta, Yap, Timothy A, Molife, L Rhoda, Kaye, Stanley B, de Bono, Johann S, Banerji, Udai
Publicado no Clin Cancer Res (2015)

MYC Amplification as a Potential Mechanism of Primary Resistance to Crizotinib in ALK-Rearranged Non-Small Cell Lung Cancer: A Brief Report()()

por Rihawi, Karim, Alfieri, Roberta, Fiorentino, Michelangelo, Fontana, Francesca, Capizzi, Elisa, Cavazzoni, Andrea, Terracciano, Mario, La Monica, Silvia, Ferrarini, Alberto, Buson, Genny, Petronini, Pier Giorgio, Ardizzoni, Andrea
Publicado no Transl Oncol (2018)

Timing and extent of response in colorectal cancer: critical review of current data and implication for future trials

por Aprile, Giuseppe, Fontanella, Caterina, Bonotto, Marta, Rihawi, Karim, Lutrino, Stefania Eufemia, Ferrari, Laura, Casagrande, Mariaelena, Ongaro, Elena, Berretta, Massimiliano, Avallone, Antonio, Rosati, Gerardo, Giuliani, Francesco, Fasola, Gianpiero
Publicado no Oncotarget (2015)

HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives

por Fanotto, Valentina, Ongaro, Elena, Rihawi, Karim, Avallone, Antonio, Silvestris, Nicola, Fornaro, Lorenzo, Vasile, Enrico, Antonuzzo, Lorenzo, Leone, Francesco, Rosati, Gerardo, Giuliani, Francesco, Bordonaro, Roberto, Scartozzi, Mario, Maglio, Giovanna De, Negri, Francesca V., Fasola, Gianpiero, Aprile, Giuseppe
Publicado no Oncotarget (2016)

A streamlined workflow for single-cells genome-wide copy-number profiling by low-pass sequencing of LM-PCR whole-genome amplification products

por Ferrarini, Alberto, Forcato, Claudio, Buson, Genny, Tononi, Paola, del Monaco, Valentina, Terracciano, Mario, Bolognesi, Chiara, Fontana, Francesca, Medoro, Gianni, Neves, Rui, Möhlendick, Birte, Rihawi, Karim, Ardizzoni, Andrea, Sumanasuriya, Semini, Flohr, Penny, Lambros, Maryou, de Bono, Johann, Stoecklein, Nikolas H., Manaresi, Nicolò
Publicado no PLoS One (2018)

Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours

por de Bono, Johann, Lin, Chia-Chi, Chen, Li-Tzong, Corral, Jesus, Michalarea, Vasiliki, Rihawi, Karim, Ong, Michael, Lee, Jih-Hsiang, Hsu, Chih-Hung, Yang, James Chih-Hsin, Shiah, Her-Shyong, Yen, Chia-Jui, Anthoney, Alan, Jove, Maria, Buschke, Susanne, Fuertig, René, Schmid, Ulrike, Goeldner, Rainer-Georg, Strelkowa, Natalja, Huang, Dennis Chin-Lun, Bogenrieder, Thomas, Twelves, Chris, Cheng, Ann-Lii
Publicado no Br J Cancer (2020)